MedTrace Logo

Sex Hormones and Orthostatic Tolerance

NCT01153581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2018-12-13

Study results available
· View outcomes & findings →

Summary

This study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. Orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.

Conditions

  • Orthostatic Intolerance

Interventions

DRUG

Ganirelix acetate

Ganirelix acetate: .25 ml/day by subcutaneous injection

DRUG

17β-Oestradiol

17 beta estradiol: 0.2 mg/day (patches)

DRUG

Progesterone

progesterone, 200 mg day-1 oral

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Nina Stachenfeld, PhD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2012-12-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153581 on ClinicalTrials.gov